Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1047-1054

  Peyrot, Mark ^a,b   Rubin, Richard R ^b   Polonsky, William H ^c   Jennie, H ^d  

^a LOYOLA UNIVERSITY MARYLAND   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Insulin; Pramlintide; Quality of life; Randomized controlled trial; Treatment satisfaction

Indexed keywords

INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; PRAMLINTIDE;

ADULT; APPETITE; ARTICLE; CLINICAL TRIAL; DIABETIC PATIENT; DISTRESS SYNDROME; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEEDING BEHAVIOR; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SIDE EFFECT; SLEEP; WEIGHT CONTROL; WEIGHT GAIN;

ADULT; AMYLOID; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE;

EID: 77951047546     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003634759     Document Type: Article

References (25)

1. Guidance for industry. Patient-reported outcome measures: use in medical product development and labeling claims. FDA/Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research/Center for Devices and Radiological Health 2006. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071975.pdf. [last accessed 14 September 2009]
2. Marra G, DIAB. & TE.S Study Group. The DIAB. & TE.S Project: how patients perceive diabetes and diabetes therapy. Acta Biomed 2004;75:164-170
3. Charpentier G, Fleury F, Dubroca I, et al. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diab Metab 2005;31: 189-195
4. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In Handbook of Psychology and Diabetes: a Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers, 1994:111-132
5. Peyrot M, Rubin RR. Assessing health-related quality of life and treatment preferences: the Insulin Delivery System Rating Questionnaire (IDSRQ). Diabetes Care 2005;28:53-58
6. Rubin RR, Peyrot M. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. The Diabetes Educator 2009;35:136-146
7. Ware JH, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36). I: Conceptual framework and item selection. Med Care 1992; 30:473-483
8. Boyer JG, Earp JL. The development of an instrument for assessing the quality of life of people with diabetes. Med Care 1997;35:440-453
9. Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care 2005;28:626-631
10. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2:113-127
11. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-2195
12. Hollander PA, Levy P, Fineman MS, et al. Pramlintide therapy as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2003;26:784-790
13. SYMLIN [package insert]. San Diego CA Amylin Pharmaceuticals 2005
14. Whitehouse F, Kruger DF, Fineman MS, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25:724-730
15. Ratner RE, Dickey R, Fineman MS, et al. Amylin replacement with pramlintide as adjunct to insulin therapy improves long-term glycemic and weight control in type 1 diabetes mellitus: a one-year randomized controlled trial. Diabet Med 2004;21:1204-1212
16. Marrero DG, Crean J, Zhang B, et al. Effect of pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2007;30:210-216 (Pubitemid 46198321)
17. Rubin RR, Peyrot M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. Curr Med Res Opin 2007; 23:1919-1929
18. Peyrot M, Rubin RR. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. Diabetes Technol Ther 2008;10:461-466
19. Riddle M, Pencek R, Charenkavanich S, et al. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009;32:1577-1582
20. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
21. Snoek FJ, Pouwer F, Welch GW, et al. Diabetes-related emotional distress in Dutch and U.S. diabetic patients: cross-cultural validity of the Problem Areas in Diabetes scale. Diabetes Care 2000;23:1305-1309
22. Glasgow RE, Fisher L, Skaff M, et al. Problem solving and diabetes self-management: investigation in a large, multiracial sample. Diabetes Care 2007;30:33-37
23. Trento M, Broglio F, Riganti F, et al. Sleep abnormalities in type 2 diabetes may be associated with glycemic control. Acta Diabetol 2008;45:225-229
24. Peyrot M, Rubin RR. How does treatment satisfaction work?: modeling determinants of treatment satisfaction and preference. Diabetes Care 2009; 32:1411-1417
25. Peyrot M, Rubin RR, Polonsky WH, et al. Clinical and patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin. Meeting abstract. Diabetes 2009;58(Suppl 1):A474